Kidney Cancer Research & Trials

Neoadjuvant Lenvatinib with Pembrolizumab in Patients with Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma

Inclusion Criteria:

• Renal mass consistent with a clinical stage ≥ T3Nx or TanyN+ or deemed unresectable by surgeon

• Locally advanced renal cell carcinoma without evidence of metastatic disease

• Renal cell carcinoma with clear cell component on pre-treatment biopsy of the primary tumor

• ECOG performance status ≤ 1 

• No hormonal therapy, chemotherapy, immunotherapy, or any other systemic therapy for a malignancy 5 years prior

Exclusion Criteria:

• Evidence of metastatic disease on pre-treatment imaging

• The subject has received any type of cytotoxic, biologic or other systemic anticancer therapy for kidney cancer

• The subject has received any other type of investigational agent within 28 days before the first dose of study treatment

• Subjects must have recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy

Principal Investigator:

Viraj Master, MD, PhD

Co-Principal Investigator:

Mehmet Bilen, MD (Department of Hematology and Medical Oncology)

Co-Investigators & Collaborators:

Haydn Kissick, PhD, Viraj Master, MD, PhD

Department of Hematology and Medical Oncology: Jacqueline Brown, MD, Christine Ertley, PA, Sarah Friend, MD, Jamie Goldman, MD, Julia Green, NP, Emilie Hitron, NP, Andrea Huffman, PA-C, Omer Kucuk, MD, David Lawson, MD, Neela Natarajan, MD, Greta Russler, MSN, FNP-BC, Stephen Szabo, MD, Lauren Yantorni, NP

Department of Biostatistics and Bioinformatics: Yuan Liu, PhD, MS

Emory Healthcare/Winship Cancer Institute: Meredith Foushee, PA, Necia Maynard, NP, ANP-BC

Glycosaminoglycan Scores for Surveillance of Recurrence in Liebovich Points >/= Non-Metastatic Clear Cell Renal Cell Carcinoma

Inclusion Criteria:

• Pre-op abdominal CT-scan
  – Primary tumor > 4cm (> cT1a)
  OR
  – ≤ 4cm if sign of venous tumor thrombus

• Elected for curative intent surgery for RCC

Exclusion Criteria:

• Metastatic disease at diagnosis

• No chest CT within 60 days before surgery

• History of other cancers not deemed fully cured

• Any other therapy than curative surgery

Principal Investigator: 

Viraj Master, MD, PhD

Co-Investigators & Collaborators: 

Kenneth Ogan, MD, Shreyas Joshi, MD

Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Tumors

Inclusion Criteria:

• Renal masses ≥ cT2

• N1 or M1 disease for surgical candidates

• Ejection fraction (EF) ≥ 45% by ECHO

Exclusion Criteria:

• Non-surgical candidate

• Unstable angina

Principal Investigator:

Viraj Master, MD, PhD

Co-Investigators & Collaborators: 

Kenneth Ogan, MD

Department of Anesthesiology: Gaurav Patel, MD, Kati Running, MD

Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer

Inclusion Criteria:

• New or recurrent low-grade, non-invasive UTUC disease

• Karnofsky Performance Status ≥ 50%

Exclusion Criteria:

• Current high-grade or muscle invasive (>pT1) urothelial carcinoma of the bladder

• Carcinoma in situ (CIS) current or previous in the upper urinary tract

• History of invasive T2 or higher urothelial cancer in past 2 years

Principal Investigator:

Kenneth Ogan, MD